CCA
AKCA

Catalyst Capital Advisors’s Akcea Therapeutics Inc AKCA Stock Holding History

Catalyst Capital Advisors’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-135
Closed -$4K – 496
2019
Q1 		$4K Buy
135
+15
+13% +$437 ﹤0.01% 381
2018
Q4 		$4K Buy
+120
New +$3.36K ﹤0.01% 393

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Catalyst Capital Advisors's AKCA Position: Q2 2019 in Review

Catalyst Capital Advisors sold out of Akcea Therapeutics Inc (AKCA) in Q2 2019, closing a stake of 135 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in AKCA in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 68 funds tracked by Wall St. Rank hold AKCA as of Q2 2019.

  • Catalyst Capital Advisors reported no remaining Akcea Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 135 Akcea Therapeutics Inc shares in Q2 2019, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Akcea Therapeutics Inc in Q4 2018 and held it in 2 quarters.
  • Catalyst Capital Advisors's Akcea Therapeutics Inc position peaked at $4K in Q1 2019.
  • 68 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2019.

Based on Catalyst Capital Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.